Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570931 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
A Phase 2 study of Infantile Neuroaxonal Dystrophy, sponsored by Biojiva.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03570931: Active Phase 2 study of Infantile Neuroaxonal Dystrophy, sponsored by Biojiva.
NCT03570931 is a Phase 2 study of Infantile Neuroaxonal Dystrophy that is active but no longer recruiting, run by Biojiva. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03570931, a Phase 2 study of Infantile Neuroaxonal Dystrophy, is active but no longer recruiting, sponsored by Biojiva.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).
Primary Outcome
Change from baseline in the Modified Ashworth spasticity scale.
Conditions Studied
Interventions
- DRUG RT001
Study Locations (2)
California
- University of California San Francisco, Benioff Children's Hospital - San Francisco
New Jersey
- Jacobs Levy Genomics and Research Program - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03570931 still lists
NCT03570931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Infantile Neuroaxonal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which RT001 is the first listed.
NCT03570931 reports a single indexed study location in California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03570931 about?
NCT03570931 is a clinical study titled "A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy". The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).
What is the current status of trial NCT03570931?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-11-05. Estimated completion is 2022-06-30.
What conditions does trial NCT03570931 study?
This clinical trial studies the following conditions: Infantile Neuroaxonal Dystrophy.
What interventions are being tested in trial NCT03570931?
The interventions under investigation include: RT001 (DRUG).
Who is sponsoring clinical trial NCT03570931?
This trial is sponsored by Biojiva, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03570931 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03570931's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI